- Home
- ATNM vs YSXT Comparison
ATNM vs YSXT Comparison
Compare ATNM & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNM | YSXT |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Automotive Aftermarket |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 24.8M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATNM | YSXT |
|---|---|---|
| Price | $1.21 | $1.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 115.6K | ★ 358.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $1.03 |
| 52 Week High | $1.95 | $9.90 |
Technical Indicators
Market Signals| Indicator | ATNM | YSXT |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 63.25 |
| Support Level | $1.02 | $1.13 |
| Resistance Level | $1.71 | $1.47 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 77.78 | 78.38 |
Price Performance
Historical ComparisonAbout ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.